This firm's average rating is Strong Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on GT Biopharma market sentiment investors' perception of the future value of GT Biopharma. Let us look at a few aspects of GT Biopharma technical analysis. About
21.0% of the company shares are held by company insiders. The book value of GT Biopharma was currently reported as 1.05. The company recorded a loss per share of
2.24. GT Biopharma had not issued any dividends in recent years. The entity had
a split on the 11th of February 2021.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of GT Biopharma. In general, sophisticated investors focus on analyzing GT Biopharma stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build GT Biopharma's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of
GT Biopharma's intrinsic value. In addition to deriving basic predictive indicators for GT Biopharma, many experienced traders also check how macroeconomic factors affect GT Biopharma price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as GT Biopharma. Your research has to be compared to or analyzed against GT Biopharma's peers to derive any actionable benefits. When done correctly, GT Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in GT Biopharma.
How does GTBP Stands against Peers?
Analyzing GT Biopharma competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to GT Biopharma across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
GT Biopharma Competition DetailsGT Biopharma Gross Profit
GT Biopharma Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing GT Biopharma previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show GT Biopharma Gross Profit growth over the last 10 years. Please check GT Biopharma's
gross profit and other
fundamental indicators for more details.
Closer look at GT Biopharma Mean Deviation
GT Biopharma has current Mean Deviation of 4.43. The mean deviation of the equity instrument is the first measure of the distances between each value of security historical prices and the mean. It gives us an idea of how spread out from the center the distribution of returns.
Mean Deviation is the average of the absolute values of the differences between price distribution numbers and their mean. Mean deviation of equity instrument with a lot of historical data is a biased estimator because the time horizon used in calculation will always be much smaller than the entire price history of the equity. The mean deviation is typically used as a measure of dispersion for small investment horizon, otherwise standard deviation is a better measure of dispersion.
Mean Deviation | = | SUM(RET DEV) N |
| = | 4.43 |
| SUM | = | Summation notation |
| RET DEV | = | Sum of return deviations of GT Biopharma |
| N | = | Number of calculation points for selected time horizon |
Let's now compare GT Biopharma Mean Deviation to its closest peers:
| GTBP | 4.430353036730946 |
| BLI | 5.4 |
| BBI | 5.68 |
Another setback for GT Biopharma insiders
Recent Market Risk Adjusted Performance is up to 0.02. Price may decline again. GT Biopharma exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate GT Biopharma individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about GT Biopharma future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure GT Biopharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact GT Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
GT Biopharma Implied Volatility
GT Biopharma's implied volatility exposes the market's sentiment of GT Biopharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GT Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GT Biopharma stock will not fluctuate a lot when GT Biopharma's options are near their expiration.
Our Final Takeaway
Although some companies in the biotechnology industry are either recovering or due for a correction, GT Biopharma may not be performing as strong as the other in terms of long-term growth potentials. While some insiders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to GT Biopharma.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of GT Biopharma. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com